The European Investment Bank (EIB) has approved a €125 million loan to support Orano Med, a subsidiary of the Orano Group, to advance its innovations in targeted cancer therapies and expand its industrial infrastructure in France.
The financing will help develop Orano Med’s lead-212–based targeted alpha therapy platform, a next-generation approach in nuclear medicine designed to selectively destroy cancer cells while limiting damage to healthy tissue. The funding will also support the construction of key production facilities, including an advanced industrial site dedicated to producing thorium-228, a critical precursor in the medical supply chain.
A central component of the investment is the development of the Advanced Thorium Extraction Facility (ATEF) in Bessines-sur-Gartempe, which will play a strategic role in scaling up the production of medical radioisotopes used in cancer treatment. Once operational, the facility is expected to supply Orano Med’s network of production sites, enabling broader access to targeted alpha therapies.
Orano Med’s research pipeline includes multiple clinical programs addressing different cancer types with significant unmet medical needs. The company collaborates with major pharmaceutical and biotech partners, reflecting growing interest in precision oncology and radioligand therapies.
The EIB emphasized that the investment aligns with broader European priorities focused on strengthening healthcare innovation, industrial capacity, and medical sovereignty. By supporting domestic production of advanced cancer therapies, the project aims to improve access to cutting-edge treatments while reinforcing Europe’s strategic healthcare infrastructure.
According to the EIB, the financing also supports the expansion of critical medical research and production capabilities within the European Union, contributing to long-term resilience in healthcare systems and ensuring a stable supply of innovative treatments for patients.
This is the second recent financing collaboration between the EIB and the Orano Group, highlighting continued investment in strategic health technologies and industrial innovation across Europe.
